Stockscreener 앱 받기
9.14
3.75%
0.33
시간 외 거래:
9.13
-0.010
-0.11%
전일 마감가:
$8.81
열려 있는:
$8.86
하루 거래량:
900.30K
Relative Volume:
1.04
시가총액:
$671.64M
수익:
$54.55M
순이익/손실:
$-193.57M
주가수익비율:
-3.1626
EPS:
-2.89
순현금흐름:
$-181.86M
1주 성능:
-5.68%
1개월 성능:
-34.24%
6개월 성능:
-61.32%
1년 성능:
-46.89%
1일 변동 폭
$8.60
$9.155
1주일 범위
$8.18
$10.39
52주 변동 폭
$8.18
$29.56
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
9.14 | 671.64M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listin - GuruFocus
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nurix Therapeutics Strengthens Workforce: 16 New Employees Receive Strategic Equity Awards - Stock Titan
160,500 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Acquired by Springhill Fund Asset Management HK Co Ltd - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $25.00 at Wells Fargo & Company - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $35.00 at Stifel Nicolaus - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Cut to $27.00 by Analysts at Needham & Company LLC - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Posts Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
ExodusPoint Capital Management LP Increases Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
UBS Adjusts Price Target on Nurix Therapeutics to $30 From $35, Keeps Buy Rating - MarketScreener
Nurix Therapeutics (NRIX) Sees Price Target Reduction Amid Ongoi - GuruFocus
Wellington Management Group LLP Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Sets New 1-Year LowTime to Sell? - MarketBeat
Grains Bottom and Why - The Globe and Mail
Nurix Therapeutics price target lowered to $25 from $32 at Wells Fargo - TipRanks
Nurix Therapeutics price target lowered to $35 from $36 at Stifel - TipRanks
50,098 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Bought by Polymer Capital Management HK LTD - MarketBeat
Nurix Therapeutics Q1 2025 Financial Highlights - TipRanks
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update | NRIX Stock News - GuruFocus
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Nurix Therapeutics Inc (NRIX) Q1 2025 Earnings: EPS of ($0.67) B - GuruFocus
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update - The Manila Times
Nurix Therapeutics Q1 Net Loss Narrows, Revenue Increases - MarketScreener
Nurix Therapeutics Inc reports results for the quarter ended February 28Earnings Summary - TradingView
Nurix Therapeutics, Inc. SEC 10-Q Report - TradingView
Nurix Scores FDA Orphan Drug Win as Q1 Revenue Jumps 11% on Sanofi Deal Success - Stock Titan
Cinctive Capital Management LP Purchases 53,744 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Geotab Wins a Google Cloud Partner of the Year Award - The Globe and Mail
Raymond James Financial Inc. Purchases Shares of 54,453 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Bryce Point Capital LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright Analysts Increase Earnings Estimates for NRIX - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 4.2%Time to Buy? - MarketBeat
Nurix Therapeutics (NRIX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 8.9%Here's What Happened - MarketBeat
NEOS Investment Management LLC Buys Shares of 22,557 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program - MSN
Nurix Therapeutics (NASDAQ:NRIX) Hits New 12-Month LowShould You Sell? - MarketBeat
Nurix expands licensing deal with Sanofi - The Pharma Letter
Nurix Therapeutics (NRIX) Surges After Licensing Deal with Sanof - GuruFocus
Sanofi licensing deal boosts Nurix shares - MSN
Nurix stock rises after Sanofi licensing deal (NRIX:NASDAQ) - Seeking Alpha
Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Expert Outlook: Nurix Therapeutics Through The Eyes Of 9 Analysts - Benzinga
Nurix Therapeutics Signs Exclusive Licensing Deal With Sanofi for Autoimmune Disease Program - MarketScreener
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases - The Manila Times
Major Pharma Deal: Nurix's AI Platform Lands $480M Potential Sanofi Partnership - Stock Titan
Trend Tracker for (NRIX) - news.stocktradersdaily.com
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.44%
자본화:
|
볼륨(24시간):